Biotech startups that raised Series A in Cambridge, Massachusetts
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Stata DX | Cambridge | Series A | $400K | 2026-02-27 |
| Prudentia Sciences | Cambridge | Series A | $20.0M | 2026-01-07 |
| Biobot Analytics | Cambridge | Series A | $13.4M | 2025-06-06 |
| Red Queen Therapeutics | Cambridge | Series A | $55.0M | 2024-08-06 |
| Nabla Bio | Cambridge | Series A | $26.0M | 2024-05-14 |
| Clasp Therapeutics | Cambridge | Series A | $150.0M | 2024-03-20 |
| Magnet Biomedicine | Cambridge | Series A | $50.0M | 2023-09-19 |
| Luminopia | Cambridge | Series A | $16.0M | 2023-06-27 |
8 rows of the CSV in 5 of its 18 columns.
- The 90 biotech startups in Cambridge, Massachusetts whose last round is Series A have raised $4.8B in total.
- 7 of them closed their most recent round in the last 12 months, $254.2M combined.
- The largest of those rounds is Stipple Bio's $100.0M Series A, dated April 2026.
- The most recent is Typewriter Therapeutics' $56.3M Series A on 2 September 2026.
- Y Combinator is an investor in 4 of them, more than any other fund.
- Health care is the most common other sector, with 83 companies (92%).
- 36% were founded in 2020 or later; the median founding year is 2018.
- The most common team size is 11 to 50 employees (59% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
6 of 90| Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|
| Stata DX | Stata DX develops eRapid disease management technology for implementing custom biomarker panels in clinical studies. | Biotech | Series A | $400K | 2026-02-27 | $3.6M | MassVentures | 1 to 10 | 2022 |
| Prudentia Sciences | Prudentia Sciences provides AI-powered asset diligence and valuation to reduce risk in drug development investment. | Artificial intelligence | Series A | $20.0M | 2026-01-07 | $27.0M | Google Ventures, Iaso Ventures, Virtue | 1 to 10 | 2023 |
| Biobot Analytics | Biobot Analytics offers a wastewater data platform that delivers population-level health insights. | Artificial intelligence | Series A | $13.4M | 2025-06-06 | $41.4M | Y Combinator, Pioneer Fund, Soma Capital +2 | 11 to 50 | 2017 |
| Nabla Bio | Nabla Bio uses an autoverse platform of biologically informed machine learning to co-develop antibody drugs. | Artificial intelligence | Series A | $26.0M | 2024-05-14 | $37.4M | Y Combinator, Khosla Ventures, National Science Foundation +2 | 11 to 50 | 2020 |
| Luminopia | Luminopia develops digital treatments for significant neuro-visual disorders. | Biotech | Series A | $16.0M | 2023-06-27 | $33.1M | MassChallenge, U.S. Venture Partners, Bantam Group +2 | 11 to 50 | 2015 |
| Dyno Therapeutics | Dyno Therapeutics uses artificial intelligence to develop gene therapies. | Artificial intelligence | Series A | $100.0M | 2021-05-06 | $109.0M | Andreessen Horowitz, Google Ventures, CRV +2 | 101 to 250 | 2018 |
Table 1. Biotech startups that raised Series A in Cambridge, Massachusetts: the 6 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 90.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Prudentia Sciences | Prudentia Sciences provides AI-powered asset diligence and valuation to reduce risk in drug development investment. | Artificial intelligence | Series A | $20.0M | 2026-01-07 | $27.0M | Google Ventures, Iaso Ventures, Virtue | 1 to 10 | 2023 |
| 2 | Stata DX | Stata DX develops eRapid disease management technology for implementing custom biomarker panels in clinical studies. | Biotech | Series A | $400K | 2026-02-27 | $3.6M | MassVentures | 1 to 10 | 2022 |
Table 2. Biotech startups that raised Series A in Cambridge, Massachusetts: the 2 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Y Combinator | Startup accelerator | Mountain View, United States | 4 | 4% | ||
| 2 | Google Ventures | Corporate venture arm | San Francisco, United States | 2 | 2% | 1 | Prudentia Sciences |
| 3 | Soma Capital | Venture capital firm | San Francisco, United States | 2 | 2% | ||
| 4 | ARCH Venture Partners | Venture capital firm | Chicago, United States | 2 | 2% | ||
| 5 | F-Prime | Venture capital firm | Cambridge, United States | 2 | 2% | ||
| 6 | MassVentures | Venture capital firm | Boston, United States | 1 | 1% | 1 | Stata DX |
| 7 | Iaso Ventures | Venture capital firm | Boston, United States | 1 | 1% | 1 | Prudentia Sciences |
| 8 | Virtue | Venture capital firm | Austin, United States | 1 | 1% | 1 | Prudentia Sciences |
| 9 | The Engine | Venture capital firm | Cambridge, United States | 1 | 1% | ||
| 10 | Pioneer Fund | Startup accelerator | Toronto, Canada | 1 | 1% | ||
| 11 | DCVC | Venture capital firm | Palo Alto, United States | 1 | 1% | ||
| 12 | Apple Tree Partners | Venture capital firm | New York, United States | 1 | 1% | ||
| 13 | National Science Foundation | Entrepreneurship program | Alexandria, United States | 1 | 1% | ||
| 14 | Khosla Ventures | Venture capital firm | Menlo Park, United States | 1 | 1% | ||
| 15 | Zetta Venture Partners | Venture capital firm | San Francisco, United States | 1 | 1% |
Table 3. Biotech startups that raised Series A in Cambridge, Massachusetts: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 83 | 92% | $4.7B |
| Software | 14 | 16% | $569.8M |
| Artificial intelligence | 9 | 10% | $321.7M |
| Hardware | 1 | 1% | $33.1M |
Table 4. Biotech startups that raised Series A in Cambridge, Massachusetts by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series A | 90 | 100% | $39.0M |
Table 5. Biotech startups that raised Series A in Cambridge, Massachusetts by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| September 2026 | 2 | 29% | $56.3M |
| April 2026 | 1 | 14% | $100.0M |
| March 2026 | 1 | 14% | $40.0M |
| February 2026 | 1 | 14% | $400K |
| January 2026 | 2 | 29% | $57.5M |
Table 6. Biotech startups that raised Series A in Cambridge, Massachusetts: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 7 | 8% | $254.2M |
| 2025 | 8 | 9% | $479.9M |
| 2024 | 8 | 9% | $442.0M |
| 2023 | 6 | 7% | $670.5M |
| 2022 | 11 | 12% | $561.3M |
| 2021 | 11 | 12% | $572.3M |
Table 7. Biotech startups that raised Series A in Cambridge, Massachusetts by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 3 | 3% |
| 2020 to 2022 | 29 | 32% |
| 2015 to 2019 | 35 | 39% |
| 2010 to 2014 | 14 | 16% |
| Before 2010 | 9 | 10% |
Table 8. Biotech startups that raised Series A in Cambridge, Massachusetts by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 29 | 32% |
| 11 to 50 | 53 | 59% |
| 51 to 100 | 3 | 3% |
| 101 to 250 | 3 | 3% |
| 251 to 500 | 1 | 1% |
| 10,001 or more | 1 | 1% |
Table 9. Biotech startups that raised Series A in Cambridge, Massachusetts by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series A and its headquarters is in Cambridge, Massachusetts. On 16 November 2026 that is 90 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 6 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 90 rows: 5 have no round amount, 0 no city and 14 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Cambridge, Massachusetts whose last round is Series A are on the list?
- 90, in the file dated 16 November 2026. 7 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 90 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.